Agilent Technologies
A · Life Sciences Tools & Services
$173.07
0.5%Danaher
DHR · Life Sciences Tools & Services
$230.50
0.3%The short version
- Danaher is the larger business, with $24.6B of revenue in fiscal 2025 against $6.9B for Agilent Technologies, about 3.5 times as much.
- Agilent Technologies grew revenue faster (6.7%, against 2.9%).
- Agilent Technologies kept more of each dollar of sales as operating profit (21.3% operating margin, against 19.1% operating margin).
- Danaher turned more of its sales into free cash flow (21.4% FCF margin, against 16.6% FCF margin).
- Agilent Technologies earned a higher return on the capital invested in it (16.5%, against 6.1%).
- Investors pay more for each dollar of Danaher’s earnings: a P/E of 37.7x against 34.1x for Agilent Technologies.
| Latest fiscal year | A · FY25 | DHR · FY25 |
|---|---|---|
| Size | ||
| Market cap | $49.0B | $162.9B |
| Revenue | $6.9B | $24.6B |
| Free cash flow | $1.2B | $5.3B |
| Net income | $1.3B | $3.6B |
| Growth | ||
| Revenue growth | 6.7% | 2.9% |
| 5-year growth | 5.4% | 2.0% |
| Share count change | −2.1% | −2.9% |
| Profitability | ||
| Gross margin | 52.4% | 59.1% |
| Operating margin | 21.3% | 19.1% |
| Net margin | 18.8% | 14.7% |
| FCF margin | 16.6% | 21.4% |
| Return on capital | 16.5% | 6.1% |
| Return on equity | 20.6% | 7.1% |
| Balance sheet | ||
| Net debt | $1.6B | $13.8B |
| Net debt / EBITDA | 0.9x | 1.9x |
| Dividends and buybacks | $707M | $4.0B |
| Valuation & quality | ||
| P/E | 34.1x | 37.7x |
| Piotroski F-score | 5 | 7 |
FY16
A $4.2B
DHR $16.9B
FY17
A $4.5B
DHR $18.3B
FY18
A $4.9B
DHR $19.9B
FY19
A $5.2B
DHR $17.9B
FY20
A $5.3B
DHR $22.3B
FY21
A $6.3B
DHR $24.8B
FY22
A $6.8B
DHR $26.6B
FY23
A $6.8B
DHR $23.9B
FY24
A $6.5B
DHR $23.9B
FY25
A $6.9B
DHR $24.6B
A
DHR
FY16
A 14.6%
DHR 16.2%
FY17
A 18.1%
DHR 14.0%
FY18
A 18.4%
DHR 15.4%
FY19
A 18.2%
DHR 18.3%
FY20
A 15.9%
DHR 19.0%
FY21
A 21.3%
DHR 25.7%
FY22
A 23.6%
DHR 28.3%
FY23
A 19.8%
DHR 21.8%
FY24
A 22.9%
DHR 20.4%
FY25
A 21.3%
DHR 19.1%
A
DHR
FY16
A $654M
DHR $2.9B
FY17
A $713M
DHR $2.9B
FY18
A $910M
DHR $3.4B
FY19
A $866M
DHR $3.3B
FY20
A $802M
DHR $5.4B
FY21
A $1.3B
DHR $7.1B
FY22
A $1.0B
DHR $7.4B
FY23
A $1.5B
DHR $5.8B
FY24
A $1.4B
DHR $5.3B
FY25
A $1.2B
DHR $5.3B
A
DHR
FY16
A 14.5%
DHR —
FY17
A 17.7%
DHR 6.2%
FY18
A 10.9%
DHR 6.8%
FY19
A 19.0%
DHR 6.9%
FY20
A 12.5%
DHR 7.9%
FY21
A 19.3%
DHR 8.9%
FY22
A 19.8%
DHR 10.4%
FY23
A 17.9%
DHR 6.7%
FY24
A 16.9%
DHR 6.3%
FY25
A 16.5%
DHR 6.1%
A
DHR
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.